Intravenous NAD vs. Oral NAD
Updated: September 24, 2026
Written or co-written by Taylor Graber, MD
Initial medical review: June 19, 2026
NAD+ is involved in cellular energy metabolism and DNA-repair processes. Those biological roles do not establish that supplementation improves wellness. This article compares routes of administration and the limits of current clinical evidence.
What Is NAD?
Nicotinamide adenine dinucleotide is a coenzyme found in cells. NAD-related biology has prompted research into supplementation, but its cellular functions should not be confused with proven improvements in energy, cognition, recovery or aging outcomes.
How Oral NAD+ Precursors Work
Oral products may contain nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), or other NAD-related compounds. These are not interchangeable with IV NAD+ itself. Oral precursors undergo digestion and metabolism; their route alone does not establish lower clinical effectiveness.
What Is NAD IV Therapy?
NAD IV therapy administers NAD+ through an intravenous infusion. Direct bloodstream delivery is a difference in route, not proof of greater cellular uptake or better clinical outcomes than oral precursors. Adding hydration does not establish NAD+ wellness benefit.
Evidence and Limits
A 2026 systematic review found changes in NAD-related biomarkers with oral precursors, while clinical wellness and anti-aging benefits remained inconclusive. Within its scope, it identified no eligible clinical outcome trials of IV or IM NAD+ itself for those indications. Direct bloodstream delivery and biomarker changes do not prove a clinical benefit or superiority over oral precursors.
The review covered studies published from January 2010 through October 2025. Its findings should not be interpreted as proof that every possible NAD-related indication is ineffective. Findings about oral NR, NMN or laboratory models cannot establish benefits of IV NAD+.
NAD IV Therapy Versus Oral Precursors
Route, cost, preparation and visit requirements differ. The cited review did not establish that IV NAD+ produces faster clinical benefits than oral precursors. A dosing schedule, bloodstream exposure or biomarker change does not establish when, or whether, an individual will notice a clinical benefit. Discuss the evidence, alternatives and uncertainties with a qualified clinician.
What About NAD+ Injections and NMN?
Intramuscular injection is another route of administration. Discuss the actual preparation, dose, visit requirements and risks with the treating clinician. A different dose or shorter visit does not establish equivalent or improved outcomes. NMN is a precursor studied in human and laboratory research; those findings should not be presented as proof of IV NAD+ efficacy or a validated long-term maintenance strategy.
Discussing Suitability with a Clinician
Persistent fatigue, difficulty concentrating and other symptoms warrant clinical assessment. They should not be assumed to indicate an NAD+ deficiency or to identify someone who will benefit from an infusion. Discuss your symptoms, medical history, medicines and alternatives with a qualified clinician before considering treatment.
Risks and When to Seek Care
The FDA has received adverse-event reports involving NAD+ injectable drugs, including severe chills, shaking, vomiting and fatigue, in its alert about unsuitable ingredients used in sterile compounding. This alert does not establish the quality or safety of a particular clinic's preparation.
Tell the treating clinician immediately if you develop concerning symptoms during an infusion. For chest pain or breathing problems, call 911 or the local emergency number. MedlinePlus provides general IV-treatment safety guidance; this is separate from NAD+ efficacy evidence and does not describe ASAP IVs' specific protocol.
Discuss NAD+ Options with ASAP IVs
ASAP IVs offers NAD+ infusion appointments. Discuss your goals, the uncertain benefits, risks and alternatives with the treating clinician before proceeding.